Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy ...

SHANGHAI, China I 19, 2024 I Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, ...

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 ...

The global hemophilia treatment market is on a strong growth ... to the U.S. Food and Drug Administration (FDA) expanding the ...

Anemia is incredibly common, especially in surgical patients, and until recently the default treatment has been blood transfusions prior to the procedure ... and patients who received a preoperative ...